Lantheus Holdings Inc
NASDAQ:LNTH

Watchlist Manager
Lantheus Holdings Inc Logo
Lantheus Holdings Inc
NASDAQ:LNTH
Watchlist
Price: 66.895 USD -0.42% Market Closed
Market Cap: $4.4B

Net Margin

11%
Current
Declining
by 5.3%
vs 3-y average of 16.3%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11%
=
Net Income
$167.7m
/
Revenue
$1.5B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
11%
=
Net Income
$167.7m
/
Revenue
$1.5B

Peer Comparison

Country Company Market Cap Net
Margin
US
Lantheus Holdings Inc
NASDAQ:LNTH
4.4B USD
Loading...
JP
Hoya Corp
TSE:7741
8.7T JPY
Loading...
CH
Alcon AG
SIX:ALC
31.5B CHF
Loading...
US
Medline Inc
NASDAQ:MDLN
37.3B USD
Loading...
DK
Coloplast A/S
CSE:COLO B
122.5B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
12.1B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.8B GBP
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
44B CNY
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.6B CHF
Loading...
KR
HLB Inc
KOSDAQ:028300
7.5T KRW
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
69th
Based on 15 072 companies
69th percentile
11%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Lantheus Holdings Inc
Glance View

Lantheus Holdings Inc. is a captivating player in the healthcare sector, primarily operating within the niche of diagnostic medical imaging. The company's core mission revolves around enhancing diagnosis and treatment pathways, thus playing an integral role in patient care. At the heart of Lantheus's operations are its innovative diagnostic and therapeutic products, including radiopharmaceuticals and contrast agents that physicians rely on to obtain detailed images of the body's organs and tissues. Through a combination of proprietary technologies and strategic partnerships, Lantheus delivers solutions that help medical professionals make more informed clinical decisions, ultimately aiming to improve patient outcomes. This business generates revenue by developing, manufacturing, and commercializing its products, which are utilized across hospitals, clinics, and research centers worldwide. By consistently investing in research and development, Lantheus ensures a competitive edge through a robust pipeline of next-generation imaging agents. Strategic alliances and collaborative ventures further fortify its market presence, allowing the company to expand its reach and integrate new advancements into its product offerings. This commitment to innovation and collaboration has not only cemented its reputation in the life sciences industry but also ensures a steady and growing stream of income from its well-regarded product lines.

LNTH Intrinsic Value
95.714 USD
Undervaluation 30%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
11%
=
Net Income
$167.7m
/
Revenue
$1.5B
What is Lantheus Holdings Inc's current Net Margin?

The current Net Margin for Lantheus Holdings Inc is 11%, which is below its 3-year median of 16.3%.

How has Net Margin changed over time?

Over the last 3 years, Lantheus Holdings Inc’s Net Margin has decreased from 13.4% to 11%. During this period, it reached a low of -1.7% on Mar 31, 2023 and a high of 33.7% on Mar 31, 2024.

Back to Top